首页> 外文期刊>Urologia internationalis >Outcome of Antegrade Radical Prostatectomy with Intended Wide Resection in Prostate Cancer Patients with a Preoperative Serum PSA Level >100 ng/ml.
【24h】

Outcome of Antegrade Radical Prostatectomy with Intended Wide Resection in Prostate Cancer Patients with a Preoperative Serum PSA Level >100 ng/ml.

机译:术前血清PSA水平> 100 ng / ml的前列腺癌患者进行彻底根治性前列腺癌根治术的结果。

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: It was the aim of this study to assess the outcome of prostate cancer patients with preoperative prostate-specific antigen (PSA) levels >/=100 ng/ml who were treated with antegrade radical prostatectomy with intended wide resection (aRP). Patients and Methods: Eighteen patients who underwent aRP had an initial PSA level >/=100 ng/ml. Overall survival, disease-specific survival and biochemical progression-free survival (bPFS) rates were determined, and predictors of treatment outcome were examined. Results: The median serum PSA level was 159.5 ng/ml. All patients but one had received neoadjuvant androgen deprivation therapy (ADT), while only 2 patients received adjuvant ADT. Five patients were classified as stage pT2, 6 as pT3a, 6 as pT3b and 1 as pT4. Four patients had locoregional lymph node metastases. Twelve patients developed PSA failure. Eight of them received salvage ADT. The estimated 10-year bPFS rate was 25.0% and the overall survival and disease-specific survival rates were 92.9 and 100%, respectively, at a median follow-up of 6 years. Multivariate analysis revealed only the clinical stage to be predictive of bPFS based on preoperative variables. On the other hand, surgical margin status, extracapsular extension and organ-confined disease were identified as being significant postoperative predictors. Conclusions: This study showed a comparatively satisfactory outcome for clinically non-metastatic prostate cancer with PSA levels >/=100 ng/ml treated by aRP.
机译:目的:本研究的目的是评估术前前列腺特异性抗原(PSA)水平> / = 100 ng / ml的前列腺癌患者,这些患者接受了顺行前列腺癌根治术并打算进行广泛切除(aRP)。患者和方法:接受aRP的18位患者的初始PSA水平> / = 100 ng / ml。确定总体生存率,疾病特异性生存率和无生化进展生存率(bPFS),并检查治疗结果的预测指标。结果:血清PSA中位数为159.5 ng / ml。除一名患者外,所有患者均接受了新辅助雄激素剥夺疗法(ADT),而只有2例患者接受了辅助ADT。五名患者被分类为pT2期,6名被分类为pT3a,6名被分类为pT3b,1名被分类为pT4。 4例患者发生局部淋巴结转移。十二名患者发生了PSA衰竭。他们中有八人获得了救助性日用品。在中位随访期为6年时,估计的10年bPFS率为25.0%,总生存率和疾病特异性生存率分别为92.9和100%。多因素分析显示,根据术前变量,仅临床阶段可预测bPFS。另一方面,手术边缘状态,囊外扩张和器官受限疾病被确定为术后重要的预测指标。结论:这项研究显示,aRP治疗的PSA水平> / = 100 ng / ml的临床非转移性前列腺癌具有相对令人满意的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号